Introduction
============

There has been an increase in the number of elderly patients with malignant disease due to rapid growth of the elderly population. Despite the development of new drugs and improvements in supportive care, treatment and the cost of patient management are emerging as important medical issues in many countries. Diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin's lymphoma, is a representative disease with increased incidence and poor prognosis in elderly patients. After introduction of rituximab (chimeric anti-CD20 monoclonal antibody), treatment outcome and prognosis of DLBCL has dramatically improved. R-CHOP (rituximab, cyclophosphamide, adriamycin, vincristine, and prednisone) is standard treatment for DLBCL \[[@b1-crt-2017-172],[@b2-crt-2017-172]\]. However, most large randomized trials enrolled patients younger than 80 years. In addition, elderly patients do not tolerate treatment to the same extent as younger patients because of comorbid diseases and organ dysfunction. Therefore, treatment strategies for very elderly patients older than 80 years have not been established because of poor tolerability and lack of data.

Recently, a multicenter, single-arm phase 2 trial reported that rituximab combined with low-dose CHOP (R-mini-CHOP) showed good results for both efficacy and safety in elderly patients older than 80 years with DLBCL \[[@b3-crt-2017-172]\]. Although this study was a phase 2 trial, the results suggested that very elderly patients could tolerate and benefit from aggressive combination chemotherapy with immunotherapy. However, no prospective data are available and only a few retrospective studies with a small number of patients over 70 years old have been conducted in Korea \[[@b4-crt-2017-172],[@b5-crt-2017-172]\]. The aim of the current study was to retrospectively investigate clinical characteristics, treatment patterns and outcomes of patients older than 80 years diagnosed with DLBCL in Korea over a 10-year period. Based on our results, we planned to perform a prospective study to identify the optimal regimen for treating DLBCL elderly patients in Korea.

Materials and Methods
=====================

This study included patients who were older than 80 years at the time of initial DLBCL diagnosis from across 19 institutions in Korea between January 2005 and June 2016. A diagnosis of DLBCL was established via tissue biopsy according to the WHO classification. Clinical and laboratory data were retrospectively obtained from hospital records.

Disease and patient-specific characteristics included age, sex, presence of co-morbidities, B symptoms, bulky disease, Eastern Cooperative Oncology Group (ECOG) performance status, complete blood count, serum lactate dehydrogenase (LDH), creatinine, β2-microglobulin, and albumin level, tumor stage, and site of extranodal disease. Staging was performed according to the criteria of the Ann Arbor system. Treatment pattern, response to treatment, toxicities, and outcome were obtained from the medical records of each patient. The Charlson comorbidity index was chosen to assess comorbidity \[[@b6-crt-2017-172]\].

A full dose of R-CHOP consisted of 375 mg/m^2^ rituximab, 750 mg/m^2^ cyclophosphamide, 50 mg/m^2^ adriamycin, and 1.4 mg/m^2^ vincristine on day 1, and 100 mg oral prednisone on days 1-5 of each cycle. The combination therapy was administered at 3-week intervals. The relative dose intensity (RDI) of these five drugs was calculated at each cycle. This study was approved by the institutional review board of each institution that participated in this study.

Overall survival was measured from the date of diagnosis of DLBCL to the date of death from any cause or the date of last follow-up. Survival curves were calculated using the Kaplan-Meier method and compared with other prognostic variables using the log-rank test. Stepwise Cox's regression analysis was performed to identify prognostic factors for survival. In all tests, p \< 0.05 was considered statistically significant.

Results
=======

1. Patient characteristics
--------------------------

A total of 194 patients aged 80 years or older at diagnosis of DLBCL were identified. The patient characteristics are summarized in [Table 1](#t1-crt-2017-172){ref-type="table"}. The study group included 93 men and 101 women, and the median age at the time of DLBCL diagnosis was 83.3 years (range, 80.1 to 95.7 years). One hundred and six patients (54.6%) had a poor performance status (ECOG 2-4) and 58% of patients had advanced stage disease (stage III or IV). LDH level was elevated in 62% of patients, and 114 (59.3%) patients had an age-adjusted International Prognostic Index (aaIPI) score of 2-3. Bone marrow biopsy was performed in 124 patients. Among these, eighteen patients showed bone marrow involvement (14.5%). The left ventricular ejection fraction, measured in 123 patients at diagnosis, was below 60% in thirteen patients (10.6%).

One hundred forty-nine patients (76.8%) had at least one comorbidity. Hypertension was the most common comorbidity followed by diabetes mellitus and cerebrovascular disease. Among the patients who presented with comorbidities, 48 (24.7%) had a Charlson index with a score 4 or more.

2. Treatments and outcomes
--------------------------

Of 194 patients with DLBCL, 154 patients (79.4%) received systemic chemotherapy, nine patients (4.6%) received radiation alone, and two patients underwent surgery only ([Table 2](#t2-crt-2017-172){ref-type="table"}). Twenty-nine patients (14.9%) received no treatment. The decision to forgo treatment was based on poor performance and/or treatment refusal. Among 154 patients who received systemic chemotherapy, R-CHOP was given in 124 cases, R-CVP (rituximab, cyclophosphamide, vincristine, and prednisone) in 13, rituximab alone in one, and other regimens in 16 cases. Of 11 patients with central nervous system lymphoma, three cases were treated with high-dose metho-trexate with or without radiation.

The median number of chemotherapy cycles was three (range, 1 to 10). Of the 154 patients who received intravenous chemotherapy, only 37 completed the planned cycles of the treatment regimen. The main causes of treatment interruption were treatment-related toxicity (45.3%) followed by treatment refusal (29.1%) and disease progression (6.8%). Forty-nine patients could not be evaluated for treatment response because of death before response assessment (18 cases), refusal (13 cases), follow-up loss (seven cases), and other causes (11 cases). The overall response rate for 154 patients who received systemic chemotherapy was 61.7%. Among 105 patients who were available for response assessment, the response rate was 90.5% with a complete response (CR) rate of 41.9% (CR, 44; partial response \[PR\], 51; stable disease \[SD\], 5; progressive disease \[PD\], 5) ([Fig. 1](#f1-crt-2017-172){ref-type="fig"}).

We performed subgroup analysis for 124 patients treated with R-CHOP because R-CHOP is standard treatment for DLBCL. The patients received a median of three cycles of R-CHOP (range, 1 to 8) and 13 patients with involved-field radiation therapy were combined. Thirty patients (24.2%) completed the planned cycles and 24 patients (19.4%) received six or more cycles of R-CHOP. The overall response rate for 124 patients who received R-CHOP was 63.7%. Among 85 patients who were available for response assessment, the response rate was 92.9% with a CR rate of 45.9% (CR, 39; PR, 40; SD, 2; PD, 4).

We calculated the RDI of five drugs at each cycle of R-CHOP ([Table 3](#t3-crt-2017-172){ref-type="table"}). The mean RDIs for doxorubicin and cyclophosphiamide in the first cycle were 64.1% and 68.2%, respectively. However, the RDIs of rituximab and prednisone were over 80%. After the first cycle, the RDI of each drug showed a similar pattern to that of the first cycle. We compared the response rate and overall survival according to RDI for R-CHOP (≥ 70% vs. \< 70% of all drugs). The overall response rate was significantly lower for high RDI group (43.5%, n=46) than for low RDI group (75.6%, n=78) (p \< 0.001). The median survival was also significantly shorter for high RDI group than for low RDI group (11.1 months vs. 25.4 months, p=0.008). The reasons of these findings may be explained that high RDI group showed higher treatment interruption rate and treatment-related mortality. Especially, 52.2% of high RDI group received only one cycle of R-CHOP.

Among the 44 patients who relapsed or progressed after first-line therapy, 26 patients received salvage therapy. Twenty-two patients were treated with various chemotherapies and three patients were treated with radiotherapy. One patient received combined treatment. The overall response rate for the salvage therapy was 61.1%. Four patients received third-line treatment ([Fig. 1](#f1-crt-2017-172){ref-type="fig"}).

3. Toxicity profiles
--------------------

The most common side effect of chemotherapy was hematologic toxicity. Neutropenia was reported in 63.0% (97/154) of patients, 91.8% (89/97) of whom had grade 3 or higher toxicity. Granulocyte colony-stimulating factor (G-CSF) was given to 73 patients during the first cycle. Forty-eight patients (31.2%) suffered neutropenic fever. Anemia was reported in 59.7% (92/154) and thrombocytopenia in 33.1% (51/154). The incidence of grade 3 or 4 toxicity of anemia and thrombocytopenia was relatively lower than that of neutropenia (27.2% and 35.3%, respectively). Infection was documented in 47 cases. Pneumonia (55.3%) was the most common infectious complication. Cardiac toxicity occurred in five cases.

Twenty-nine patients died due to treatment-related toxicity. Among them, 13 patients died after the first cycle of chemotherapy and the main causes of death were pneumonia and sepsis (10 cases). Of 124 patients treated with R-CHOP, the treatment-related mortality rate was 16.9% (21/124). However, among 19 patients who received the full dose of R-CHOP, six patients died due to toxicity (31.6%).

4. Survival analyses
--------------------

One hundred and seven patients died with a median survival of 14.0 months ([Fig. 2](#f2-crt-2017-172){ref-type="fig"}). Of 124 patients treated with R-CHOP, median overall survival was 18.5 months. The main causes of death were disease progression (33 cases, 30.8%) and treatment-related toxicity (29 cases, 27.1%). The cause of death according to treatment is shown in [Table 4](#t4-crt-2017-172){ref-type="table"}. In the univariate analysis, significant prognostic factors for overall survival were ECOG performance status, serum LDH, number of extranodal sites, aaIPI, anemia, hypoalbuminemia, elevated creatinine, co-morbidity, and treatment ([Table 5](#t5-crt-2017-172){ref-type="table"}). There was no significant survival difference between R-CHOP and less intensive treatment group (p=0.870) ([Fig. 2C](#f2-crt-2017-172){ref-type="fig"}). However, we found significant difference in the median survival according to number of chemotherapy cycles (\< 4 cycles vs. ≥ 4 cycles) (11.1 months vs. 26.6 months, p=0.003) ([Fig. 2D](#f2-crt-2017-172){ref-type="fig"}). In multivariate analyses using the significant prognostic variables from univariate analysis, overall survival was affected by aaIPI, hypoalbuminemia, elevated creatinine, and treatment ([Table 6](#t6-crt-2017-172){ref-type="table"}).

Discussion
==========

In this study, we found that more than half of very elderly patients with DLBCL (63.9%) who received R-CHOP had a high response rate of 92.9% (CR, 45.9%) in Korea. However, our study showed a high treatment-related mortality rate due to infection with severe neutropenia, especially after the first cycle of chemotherapy. Significant prognostic factors for overall survival included aaIPI, hypoalbuminemia, elevated creatinine, and treatment.

The treatment strategy for elderly patients older than 80 years with DLBCL has not been defined yet because of poor treatment tolerability and lack of data. Retrospective studies have reported that elderly patients have worse outcomes due to suboptimal therapy and toxicity; however, some patients achieved a CR and long-term survival \[[@b7-crt-2017-172],[@b8-crt-2017-172]\]. There have been several trials that sought to reduce toxicity and to identify optimal regimens in elderly patients. "Prephase treatment" has been proposed in order to reduce "first-cycle effects," which refer to side effects of the first chemotherapy cycle such as the deepest neutrophil nadir, longest neutropenic duration, tumor lysis syndrome and highest rate of treatment-related mortality \[[@b9-crt-2017-172]\]. Prephase treatment consisted of oral prednisone for 5 to 7 days alone or with single injection of 1 mg vincristine before the first chemotherapy cycle. After introduction of the prephase treatment, the number of treatment-related deaths was significantly decreased and the performance status was improved. Therefore, the author recommends prephase treatment for all elderly patients \[[@b10-crt-2017-172]\].

In the search for adequate therapy of very elderly or frail patients, several alternative regimens have been reported \[[@b11-crt-2017-172]-[@b15-crt-2017-172]\]. Among them, R-miniCHOP data showed good results of both efficacy and safety in 149 elderly patients older than 80 years with DLBCL. This study reported that the median overall survival was 29 months with a 62% CR and unconfirmed CR rate. However, only 12 deaths were related to treatment toxicity \[[@b3-crt-2017-172]\]. R-miniCHOP consisted of 375 mg/m^2^ rituximab, 400 mg/m^2^ cyclophosphamide, 25 mg/m^2^ adriamycin, and 1 mg vincristine on day 1, and 40 mg/m^2^ oral prednisone on days 1 through 5 of each cycle at 3-week intervals. The doses of each drug were similar to the mean dose intensity of R-CHOP in our study. In addition, our data revealed high treatment-related mortality in patients treated with full dose R-CHOP. Therefore, we suggest that R-miniCHOP is an acceptable regimen for very elderly patients based on results from actual clinical practice.

In addition, supportive care including careful monitoring, prophylaxis and treatment for infection should be included to reduce morbidity and mortality. The American Society of Clinical Oncology guideline for the use of G-CSF recommends prophylactic G-CSF in elderly patients receiving CHOP or R-CHOP \[[@b16-crt-2017-172]\]. In our study, grade 3 or 4 neutropenia was the most common severe side effect of chemotherapy and infection-associated neutropenia was the most common cause of treatment-related death. More than three-fourths of neutropenia cases (78.4%) developed after the first cycle and 13 patients died due to toxicity just after the first cycle. These results demonstrate that prophylactic G-CSF is essential for treating R-CHOP in elderly patients.

The therapeutic goal in treating very elderly DLBCL patients is to balance between efficacy and toxicity of treatment. Therefore, it is important to identify patients who will tolerate and respond to treatment. A low serum albumin level is a significant parameter associated with poor outcome in our study. The finding that hypoalbuminemia is a poor prognostic factor was consistent with results from previous reports \[[@b3-crt-2017-172],[@b4-crt-2017-172]\]. Hypoalbuminemia reflects malnutrition, inflammation and advanced disease. Therefore, a low serum albumin concentration might be an important parameter for the ability to tolerate treatment.

In the present study, the CR rate was lower than that from a previous study. The cause of the lower CR rate may be high incidence of treatment interruption and reduced dose intensity. Response to first-line therapy is more important in elderly patients since adequate salvage therapy is usually difficult in these patients. Therefore, a well-designed prospective randomized trials for searching optimal regimens for the very elderly patients with DLBCL is needed.

The present study had several limitations. First, the clinical data, including treatment, side effects, relapse and survival data, were analyzed retrospectively. There were concerns of under-reporting and reporting bias, especially with toxicity profiles and patients lost to follow-up. In addition, treatment modality was not pre-determined. However, this study is one of the largest analyses of DLBCL patients older than 80 years and our results reflect the actual clinical practice in Korea.

These results suggest that age itself should not be a major influence on treatment decision-making by clinicians and adequate therapy should be considered in elderly DLBCL patients. However, since elderly patients show higher treatment-related mortality due to infection, careful monitoring and dose modification of chemotherapeutic agents is needed. Based on these results, we plan to perform a prospective study of R-miniCHOP with prephase treatment and prophylactic G-CSF in very elderly patients older than 80 years with DLBCL in Korea.
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###### 

Patient characteristics

  Characteristic                                No. (%) (n=194)
  --------------------------------------------- ------------------
  **Sex**                                       
   Male                                         93 (47.9)
   Female                                       101 (52.1)
  **Age, median (range, yr)**                   83.3 (80.1-95.7)
  **Performance status (ECOG)**                 
   0-1                                          88 (45.4)
   2-4                                          106 (54.6)
  **Ann Arbor stage (n=193)**                   
   I-II                                         81 (42.0)
   III-IV                                       112 (58.0)
  **LDH level (n=192)**                         
   Normal                                       73 (38.0)
   Abnormal                                     119 (62.0)
  **No. of extranodal sites (n=193)**           
   \< 2                                         154 (79.8)
   ≥ 2                                          39 (20.2)
  **aaIPI (n=192)**                             
   0                                            22 (11.5)
   1                                            56 (29.2)
   2                                            64 (33.3)
   3                                            50 (26.0)
  **B symptoms**                                41/176 (23.3)
  **Bulky disease**                             15/185 (8.1)
  **Elevated β2-microglobulin**                 64/89 (71.9)
  **Anemia (hemoglobin \< 12 g/dL)**            118/194 (60.8)
  **Thrombocytopenia**                          36/194 (18.6)
  **Hypoalbuminemia (\< 3.5 g/dL)**             82/193 (42.3)
  **Renal failure (creatinine \> 1.5 mg/dL)**   18/193 (9.3)
  **Comorbidity (Charlson CSS)**                
   0-3                                          146 (75.3)
   ≥ 4                                          48 (24.7)

Values are presented as number (%) unless otherwise indicated.

ECOG, Eastern Cooperative Oncology Group; LDH, lactate dehydrogenase; aaIPI, age-adjusted International Prognostic Index; CSS, comorbidity scoring system.

###### 

Treatment details

  Treatment                       No. (%)
  ------------------------------- ------------
  **No treatment**                29 (14.9)
  **Operation (tumor removal)**   2 (1.0)
  **Radiation alone**             9 (4.6)
  **First-line chemotherapy**     154
   R-CHOP                         124 (63.9)
   R-CVP                          13 (6.7)
   CVP                            8 (4.1)
   R alone                        1 (0.5)
   Other                          8 (4.1)
  **Second-line chemotherapy**    26
  **Third-line chemotherapy**     4

R-CHOP, rituximab, cyclophosphamide, adriamycin, vincristine, and prednisone; R, rituximab; CVP, cyclophosphamide, vincristine, and prednisone.

###### 

Relative dose intensity and TRD of R-CHOP

                 No. of patients   Relative dose intensity (%)   TRD                         
  -------------- ----------------- ----------------------------- ------ ------ ------ ------ ----
  First cycle    124               86.8                          68.2   64.1   74.1   84.0   12
  Second cycle   95                84.8                          65.0   60.0   70.4   80.1   2
  Third cycle    76                83.2                          64.5   58.0   68.9   80.5   3
  Fourth cycle   53                81.3                          62.5   58.0   68.3   80.7   0
  Fifth cycle    35                85.4                          60.8   56.7   64.7   77.9   4
  Sixth cycle    24                96.9                          69.6   65.5   80.3   89.9   0

TRD, treatment-related death; R-CHOP, rituximab, cyclophosphamide, adriamycin, vincristine, and prednisone.

###### 

Cause of death according to treatment

  Treatment         No. of patients   Death   Disease progression   Cause of death                                           
  ----------------- ----------------- ------- --------------------- --------------------------------------------------- ---- ----
  R-CHOP            124               63      17                    22^[a)](#tfn1-crt-2017-172){ref-type="table-fn"}^   10   14
  Other treatment   41                19      3                     7                                                   3    6
  No treatment      29                25      13                    0                                                   6    6
  Total             194               107     33                    29                                                  19   26

R-CHOP, rituximab, cyclophosphamide, adriamycin, vincristine, and prednisone.

One patient died due to treatment-related toxicity after salvage therapy.

###### 

Univariate analysis of prognostic factors for overall survival

  Prognostic factor                Survival (median±SE, mo)   p-value
  -------------------------------- -------------------------- ----------
  **aaIPI**                                                   
   0                               Not reached                \< 0.001
   1                               19.3±5.1                   
   2                               14.0±6.5                   
   3                               7.7±2.8                    
  **ECOG**                                                    
   0-1                             24.3±11.2                  \< 0.001
   2-4                             7.9±1.7                    
  **Stage**                                                   
   I-II                            18.5±6.5                   0.088
   III-IV                          11.1±2.2                   
  **LDH**                                                     
   Normal                          18.5±3.0                   0.016
   Elevated                        10.7±2.4                   
  **No. of extranodal sites**                                 
   \< 2                            16.0±2.7                   0.032
   ≥ 2                             9.3±1.8                    
  **Hemoglobin (g/dL)**                                       
   \< 12                           11.1±1.9                   0.005
   ≥ 12                            21.6                       
  **Albumin (g/dL)**                                          
   \< 3.5                          6.4±0.9                    \< 0.001
   ≥ 3.5                           21.0±3.3                   
  **Creatinine (mg/dL)**                                      
   \< 1.5                          16.9±2.6                   0.001
   ≥ 1.5                           4.6±2.8                    
  **Comorbidity (Charlson CSS)**                              
   \< 4                            17.5±3.1                   0.013
   ≥ 4                             10.4±1.8                   
  **Treatment**                                               
   R-CHOP                          18.5±3.8                   \< 0.001
   Other treatment                 12.9±4.3                   
   No treatment                    2.7±1.9                    

SE, standard error; aaIPI, age-adjusted International Prognostic Index; ECOG, Eastern Cooperative Oncology Group; LDH, lactate dehydrogenase; CSS, comorbidity scoring system; R-CHOP, rituximab, cyclophosphamide, adriamycin, vincristine, and prednisone.

###### 

Multivariate analysis of prognostic factors for overall survival

  Prognostic factor            Hazard ratio (95% CI)   p-value
  ---------------------------- ----------------------- ----------
  aaIPI                        1.358 (1.082-1.704)     0.008
  Anemia                       1.276 (0.812-2.005)     0.291
  Hypoalbuminemia              1.991 (1.292-3.069)     0.002
  Increased creatinine         2.568 (1.424-4.632)     0.002
  Comorbidity (Charlson CSS)   1.540 (0.987-2.403)     0.057
  No treatment                 1.642 (1.274-2.117)     \< 0.001

CI, confidence interval; aaIPI, age-adjusted International Prognostic Index; CSS, comorbidity scoring system.
